LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 152

Search options

  1. Article ; Online: The pressing need for a global HEV vaccine.

    Peron, Jean-Marie / Larrue, Hélène / Izopet, Jacques / Buti, Maria

    Journal of hepatology

    2023  Volume 79, Issue 3, Page(s) 876–880

    Abstract: Based on the worldwide distribution of hepatitis E virus (HEV) and its ability to cause major epidemics in low-income countries, the global availability of a HEV vaccine is a pressing clinical need. Populations at risk of severe forms of the infection ... ...

    Abstract Based on the worldwide distribution of hepatitis E virus (HEV) and its ability to cause major epidemics in low-income countries, the global availability of a HEV vaccine is a pressing clinical need. Populations at risk of severe forms of the infection are well characterised: patients with chronic liver disease - at risk of liver failure; pregnant women - at risk of fulminant hepatitis or obstetrical complications; and immunosuppressed patients, particularly those with solid organ transplants - at risk of chronic hepatitis and rapid progression to cirrhosis. Only one hepatitis E vaccine is presently being manufactured. It has been proven to be effective and safe. However, its accessibility, as well as data on its long-term efficacy and the duration of protection it confers, are limited. While individuals considered to be at risk of severe infection appear to be ideal targets for the vaccine, its effectiveness and tolerability have not yet been studied in populations with chronic liver disease and immunosuppressed patients. Hepatitis E vaccination could also play an important role in controlling outbreaks in large waterborne epidemics. Clinical trials on these populations are needed.
    MeSH term(s) Humans ; Female ; Pregnancy ; Hepatitis E virus ; Hepatitis E/epidemiology ; Hepatitis E/prevention & control ; Hepatitis E/complications ; Liver Cirrhosis/complications ; Hepatitis, Chronic/complications ; Vaccines/therapeutic use
    Chemical Substances Vaccines
    Language English
    Publishing date 2023-03-30
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2023.03.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: An Unusual Case of Budd-Chiari Syndrome: Diagnosis and Treatment.

    Le Cosquer, Guillaume / Brunac, Anne Cécile / Peron, Jean Marie

    Gastroenterology

    2022  Volume 163, Issue 2, Page(s) e4–e5

    MeSH term(s) Budd-Chiari Syndrome/diagnostic imaging ; Budd-Chiari Syndrome/therapy ; Hepatic Veins ; Humans
    Language English
    Publishing date 2022-02-08
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2022.01.049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Hepatitis E Virus Infection and Cirrhosis of the Liver.

    Péron, Jean-Marie

    Gastroenterology & hepatology

    2016  Volume 12, Issue 9, Page(s) 565–567

    Language English
    Publishing date 2016-08-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Hepatitis E, what is the real issue?

    Larrue, Hélène / Abravanel, Florence / Peron, Jean-Marie

    Liver international : official journal of the International Association for the Study of the Liver

    2021  Volume 41 Suppl 1, Page(s) 68–72

    Abstract: Hepatitis E virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis with an estimated 3.3 million symptomatic cases every year and 44,000 related deaths. It is a waterborne infection in the developing countries. In ... ...

    Abstract Hepatitis E virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis with an estimated 3.3 million symptomatic cases every year and 44,000 related deaths. It is a waterborne infection in the developing countries. In these countries, HEV genotypes 1 and 2 cause large outbreaks and affect young subjects resulting in significant mortality in pregnant women and patients with cirrhosis. In developed countries, HEV genotypes 3 and 4 are responsible for autochthonous, sporadic hepatitis and transmission is zoonotic. Parenteral transmission by the transfusion of blood products has been identified as a potential new mode of transmission. HEV can also cause neurological disorders and chronic infections in immunocompromised patients. The progression of acute hepatitis E is usually asymptomatic and resolves spontaneously. Diagnosis is based on both anti-HEV IgM antibodies in serum and viral RNA detection in blood or stools by PCR in immunocompetent patients, while only PCR is validated in immunocompromised individuals. Ribavirin is the only validated treatment in chronic infection. A vaccine has been developed in China.
    MeSH term(s) China ; Female ; Hepatitis Antibodies ; Hepatitis E/diagnosis ; Hepatitis E/epidemiology ; Hepatitis E virus/genetics ; Humans ; Pregnancy ; Ribavirin
    Chemical Substances Hepatitis Antibodies ; Ribavirin (49717AWG6K)
    Language English
    Publishing date 2021-05-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2102783-3
    ISSN 1478-3231 ; 1478-3223
    ISSN (online) 1478-3231
    ISSN 1478-3223
    DOI 10.1111/liv.14880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Diagnostic and management strategies for chronic hepatitis E infection.

    Abravanel, Florence / Lhomme, Sébastien / Marion, Olivier / Péron, Jean Marie / Kamar, Nassim / Izopet, Jacques

    Expert review of anti-infective therapy

    2023  Volume 21, Issue 2, Page(s) 143–148

    Abstract: Introduction: Hepatitis E Virus (HEV) was initially thought to cause only acute infections, but the discovery of chronic hepatitis E in immunocompromised patients has profoundly changed our understanding of the virus.: Areas covered: We describe the ... ...

    Abstract Introduction: Hepatitis E Virus (HEV) was initially thought to cause only acute infections, but the discovery of chronic hepatitis E in immunocompromised patients has profoundly changed our understanding of the virus.
    Areas covered: We describe the physiopathology, diagnosis, and clinical management of chronic HEV infection. The virus can persist in nearly two-thirds of immunosuppressed patients. Reducing immunosuppression is the first immunomodulatory strategy to cure chronic hepatitis E. But this may not always be feasible or effective. Ribavirin monotherapy for 3 months has been recommended as first-line treatment for chronically infected patients. Ribavirin is around 80% effective at eradicating HEV in retrospective studies. Apart from ribavirin, interferon has been successfully used in liver transplants recipients, but if the patient does not respond, no other alternative drug is available. The vaccine available to prevent HEV infection is one available only in China.
    Expert opinion: HEV infection is a major concern in immunocompromised patients. But the therapeutic arsenal is limited to ribavirin and interferon. Both produce several side effects and new drugs are urgently needed. Moreover, preventive strategies to limit HEV transmission and/or evolution to a chronic infection are also required.
    MeSH term(s) Humans ; Hepatitis E/diagnosis ; Hepatitis E/drug therapy ; Hepatitis E/prevention & control ; Ribavirin/therapeutic use ; Antiviral Agents/therapeutic use ; Persistent Infection ; Retrospective Studies ; Hepatitis E virus ; Interferons ; Immunocompromised Host
    Chemical Substances Ribavirin (49717AWG6K) ; Antiviral Agents ; Interferons (9008-11-1)
    Language English
    Publishing date 2023-01-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2023.2166932
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Modified PSYCHE NMR - The possibility for the direct semi-quantitation of components in mixtures.

    Durrant, Arija / Peron, Jean-Marie R / Langat, Moses K / Robertson, Cameron / Le Gresley, Adam

    Talanta

    2023  Volume 268, Issue Pt 1, Page(s) 125332

    Abstract: A series of commonly occurring biologically relevant compounds were analysed using internally referenced PSYCHE NMR and the accuracy/precision compared with that achieved using conventional qNMR. The effect of chemical shift, coupling constants, swept ... ...

    Abstract A series of commonly occurring biologically relevant compounds were analysed using internally referenced PSYCHE NMR and the accuracy/precision compared with that achieved using conventional qNMR. The effect of chemical shift, coupling constants, swept frequency pulse angle, excitation sculpting and the impact of signal overlap in mixtures was evaluated in terms of statistically significant variation between the two techniques. It is shown that suitably optimised PSYCHE NMR represents a potentially reliable method for the semi-quantitation of mixtures of compounds, whose spectroscopic signals overlap in conventional qNMR analysis and hence cannot be accurately quantified with that technique. This is of particular relevance for complex mixtures of natural products. Of particular note is the effect of the excitation sculpting block introduced to supress baseline artefacts.
    Language English
    Publishing date 2023-10-22
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1500969-5
    ISSN 1873-3573 ; 0039-9140
    ISSN (online) 1873-3573
    ISSN 0039-9140
    DOI 10.1016/j.talanta.2023.125332
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Hepatitis E, what's the real issue?

    Larrue, Hélène / Abravanel, Florence / Péron, Jean-Marie

    Liver international : official journal of the International Association for the Study of the Liver

    2020  Volume 40 Suppl 1, Page(s) 43–47

    Abstract: Hepatitis E Virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis in the world with an estimated 20 million cases every year and 70 000 deaths. Hepatitis E is a waterborne infection in the developing countries. In ... ...

    Abstract Hepatitis E Virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis in the world with an estimated 20 million cases every year and 70 000 deaths. Hepatitis E is a waterborne infection in the developing countries. In these countries, HEV genotypes 1 and 2 cause large outbreaks and affect young subjects, resulting in significant mortality in pregnant women and patients with cirrhosis. In the developed countries, HEV genotypes 3 and 4 are responsible for autochthonous, sporadic hepatitis and transmission is zoonotic. Parenteral transmission by the transfusion of blood products has been identified as a potential new mode of transmission. The prevalence of positive HEV viraemia in blood donors in Europe ranges from 1/600 to 1/2500 in highly endemic European countries. HEV can cause neurological disorders and chronic infections in immunocompromised patients. The progression of acute hepatitis E is usually asymptomatic and resolves spontaneously. Diagnostic tools include anti-HEV IgM antibodies in serum and/or viral RNA detection in the blood or the stools by PCR. Ribavirin is used to treat chronic infection. A vaccine has been developed in China.
    MeSH term(s) China ; Europe/epidemiology ; Female ; Hepatitis Antibodies ; Hepatitis E/diagnosis ; Hepatitis E/drug therapy ; Hepatitis E/epidemiology ; Hepatitis E virus/genetics ; Humans ; Pregnancy ; RNA, Viral
    Chemical Substances Hepatitis Antibodies ; RNA, Viral
    Language English
    Publishing date 2020-03-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2102783-3
    ISSN 1478-3231 ; 1478-3223
    ISSN (online) 1478-3231
    ISSN 1478-3223
    DOI 10.1111/liv.14351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Evaluation of an automated platform for the detection of HEV RNA in plasma and stool.

    Sottil, Pauline / Lhomme, Sébastien / Saune, Karine / El Hayani, Soheil / Oliveira-Mendes, Kévin / Peron, Jean-Marie / Kamar, Nassim / Izopet, Jacques / Abravanel, Florence

    Journal of virological methods

    2024  Volume 327, Page(s) 114920

    Abstract: Introduction: We evaluated the performance of the automated Altostar HEV RNA platform for detecting HEV RNA.: Methods and results: Clinical performance was determined by testing 81 plasma samples and 10 fecal samples manually quantified previously ... ...

    Abstract Introduction: We evaluated the performance of the automated Altostar HEV RNA platform for detecting HEV RNA.
    Methods and results: Clinical performance was determined by testing 81 plasma samples and 10 fecal samples manually quantified previously with the Realstar RT-PCR assay using the Magnapure instrument for extraction. The assays were concordant for 79/81 plasma samples (97.5%) and 10/10 (100%) fecal samples. The two plasma samples that tested negative with the Altostar assay had a very low HEV RNA concentration (1.6 and 1.4 log
    Conclusions: The Altostar platform enables highly accurate testing for the detection of HEV RNA in stool and the quantification of HEV RNA in plasma. This allowed us to shorten turnaround times and to save time for the technical staff.
    Language English
    Publishing date 2024-04-03
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 8013-5
    ISSN 1879-0984 ; 0166-0934
    ISSN (online) 1879-0984
    ISSN 0166-0934
    DOI 10.1016/j.jviromet.2024.114920
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Curative surgical treatment of common bile duct stones: Retrospective cohort study.

    Pouplin, Julien / Maulat, Charlotte / Yubero, Gabriel / Shourick, Jason / Cuellar, Emmanuel / Culetto, Adrian / Barange, Karl / Buscail, Louis / Carrere, Nicolas / Peron, Jean-Marie / Suc, Bertrand / Bournet, Barbara / Boulard, Paul / Muscari, Fabrice

    World journal of surgery

    2024  Volume 48, Issue 3, Page(s) 692–700

    Abstract: Background: In the event of symptomatic common bile duct (CBD) stones with dilated CBD, one possible curative treatment option is stone extraction through choledocotomy associated with cholecystectomy. Endoscopic treatment is only reserved for residual ... ...

    Abstract Background: In the event of symptomatic common bile duct (CBD) stones with dilated CBD, one possible curative treatment option is stone extraction through choledocotomy associated with cholecystectomy. Endoscopic treatment is only reserved for residual stones at 6 weeks. The aim of this study was to evaluate the results from laparoscopic curative surgical treatment of CBD stones with dilated CBD.
    Methods: This is a retrospective single-centered cohort study. All consecutive patients admitted for laparoscopic cholecystectomy with evidence of CBD stones with dilated CBD from January 2010 to December 2020 at our center were included. Success was defined by CBD clearance at 6 weeks. Need for additional procedures, such as endoscopic sphincterotomy, immediate, and end-of-procedure morbi-mortality as well as factors associated with procedure failure, were also studied.
    Results: A total of 246 patients who received curative treatment were included in the study. The success rate for the curative treatment was 93.1% (229 patients). Immediate postoperative morbidity was 24.4% with a 5.3% reintervention rate. Immediate and 6-week postoperative mortality rates were zero and 0.4%, respectively. The mean length of stay was 11.3 days. Factors associated with procedure failure appeared to be the occurrence of an early postoperative complication and the need for readmission during the period between surgery and drain removal.
    Conclusion: This study indicates that laparoscopic curative surgical treatment for symptomatic CBD stones may be performed with acceptable results without routine need for additional procedures.
    MeSH term(s) Humans ; Retrospective Studies ; Cohort Studies ; Cholangiopancreatography, Endoscopic Retrograde/methods ; Gallstones/surgery ; Gallstones/complications ; Sphincterotomy, Endoscopic/adverse effects ; Sphincterotomy, Endoscopic/methods ; Cholecystectomy, Laparoscopic/methods ; Common Bile Duct/surgery ; Choledocholithiasis/surgery
    Language English
    Publishing date 2024-02-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 224043-9
    ISSN 1432-2323 ; 0364-2313
    ISSN (online) 1432-2323
    ISSN 0364-2313
    DOI 10.1002/wjs.12093
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: In situ

    Peron, Jean-Marie R / Packman, Hollie / Peveler, William J / Bear, Joseph C

    RSC advances

    2020  Volume 10, Issue 23, Page(s) 13369–13373

    Abstract: We have investigated ... ...

    Abstract We have investigated the
    Language English
    Publishing date 2020-04-01
    Publishing country England
    Document type Journal Article
    ISSN 2046-2069
    ISSN (online) 2046-2069
    DOI 10.1039/c9ra10122e
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top